SCHEMBL4821092

SCHEMBL4821092

FC(F)(F)c1ccccc1-c1c(Cl)nc2ncnn2c1N1CCC(Cl)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 2/20 0.38
HPGD P15428 2/20 0.38
CYP3A4 P08684 2/20 0.38
SMN1; SMN2 Q16637 4/20 0.37
LMNA P02545 3/20 0.37
TSHR P16473 3/20 0.37
NPSR1 Q6W5P4 3/20 0.37
MAPT P10636 2/20 0.37
HTT P42858 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
RORC P51449 1/20 0.36
ALDH1A1 P00352 3/20 0.35
GLA P06280 1/20 0.35
MBOAT4 Q96T53 2/20 0.35
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
CYP1A2 P05177 5/20 0.34
CYP2C19 P33261 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4820359 0.88 CNR2 (0.39) PDE2AHPGDCYP3A4SMN1; SMN2LMNA
SCHEMBL4821049 0.79 TSHR (0.42) PDE2ASMN1; SMN2LMNATSHRNPSR1
SCHEMBL4819333 0.78 PDE2A (0.39) PDE2ASMN1; SMN2LMNATSHRNPSR1
SCHEMBL8917364 0.78 LMNA (0.44) PDE2ASMN1; SMN2LMNATSHRNPSR1
SCHEMBL8916382 0.75 LMNA (0.41) PDE2AHPGDSMN1; SMN2LMNATSHR
SCHEMBL8912330 0.73 TSHR (0.41) PDE2AHPGDSMN1; SMN2LMNATSHR
SCHEMBL4819468 0.72 TSHR (0.39) PDE2ASMN1; SMN2LMNATSHRNPSR1
SCHEMBL4820762 0.72 TSHR (0.39) CYP3A4SMN1; SMN2LMNATSHRNPSR1
SCHEMBL15341363 0.71 LMNA (0.43) PDE2ASMN1; SMN2LMNATSHRNPSR1
SCHEMBL5228613 0.71 LMNA (0.48) PDE2AHPGDSMN1; SMN2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1307200-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS Wyeth (US) 2003-05-07 EP claimed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US claimed
WO-2002002563-A2 SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS WYETH (US) 2002-01-10 WO claimed
US-7329663-B2 Substituted-triazolopyrimidines as anticancer agents WYETH (US) 2008-02-12 US disclosed
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents AMERICAN HOME PRODUCTS CORPORATION 2002-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020068744-A1 Substituted-triazolopyrimidines as anticancer agents TUBB3, TUBA1C, TUBB1 PDE2A 3218/4885HPGD 3005/4885CYP3A4 3639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.